Micro Digital Co. Ltd

Micro Digital Co. Ltd

305090 · KQ · Healthcare / Medical Devices

538.00KRW-230.00 (-29.95%)

Price History

Full chart

Market Stats

Previous Close768.00
Open538.00
Day Range538.00 – 579.00
52-Week Range538.00 – 11,930.00
Volume0
Market Cap10.00B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.97
50-Day Avg1,235.38
200-Day Avg5,015.26

About

Micro Digital Co., Ltd. develops, manufactures, and sells biomedical and bioprocess solutions in South Korea and internationally. The company offers biomedical lab instruments comprising Nabi, a UV/vis nano spectrophotometer; Mobi, a microplate spectrophotometer; Ubi-490, a UV/vis spectrophotometer; Ubi-600, a UV/vis standalone spectrophotometer; Ubi-800, a UV/vis double beam spectrophotometer; Lumi, a single tube luminometer; Lubi Plus, a microplate luminometer; and iSBS, an integrated sample banking system. It also provides biomedical in vitro diagnostic products consisting of DxBIC, an immunoassay automation platform. In addition, the company offers single-use bioreactor systems, such as CELBIC 5, CELBIC 25/50, CELBIC 100, CELBIC 200, CELBIC 500, and CELBIC 1000. Further, it provides bioprocess consumables, including 3D disposable cell culture bags; and 2D disposable storage, transfer, and sampling bags. The company serves CMOs and CDMOs, pharmaceutical companies, universities, research institutes, and alternative meat companies. Micro Digital Co., Ltd. was founded in 2002 and is headquartered in Seongnam-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEONam Kim Kyung
  • Employees0
  • HeadquartersOpmu B-dong, Seongnam-si, South Korea, Korea
  • Websitehttps://www.md-best.com

Leadership

  • Nam Kim KyungChief Executive Officer
  • Mr. SungDae KimExecutive Director · b. 1970
  • Chung-Wan LeeUnregistered Executive

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue6.06B4.37B4.55B4.72B3.93B2.29B4.30B8.88B10.84B11.53B12.84B
Growth (%)--27.82%+4.16%+3.72%-16.88%-41.67%+87.96%+106.38%+22.02%+6.40%+11.35%
Cost of Revenue4.07B2.66B2.44B3.15B4.09B4.75B3.31B8.66B4.67B5.34B9.20B
Gross Profit1.99B1.72B2.12B1.57B-160.22M-2.46B990.54M228.37M6.17B6.20B3.64B
Gross Margin32.88%39.27%46.47%33.28%-4.08%-107.22%23.01%2.57%56.94%53.72%28.34%
Operating Expense1.49B1.68B1.62B2.91B6.21B8.56B7.57B8.18B5.28B6.01B12.81B
Operating Income499.96M32.23M492.74M-1.33B-6.37B-11.02B-6.58B-7.95B889.58M184.59M-9.17B
Operating Margin8.25%0.74%10.82%-28.23%-162.28%-481.08%-152.86%-89.52%8.21%1.60%-71.41%
EBITDA--------6.27B3.93B3.72B-9.48B
EBITDA Margin--------70.59%36.22%32.28%-73.79%
Net Income3.38M-3.28B-29.78M-1.66B-6.30B-10.47B-7.63B-9.36B590.14M449.55M-13.15B
Net Income Margin0.06%-75.13%-0.65%-35.07%-160.39%-457.11%-177.21%-105.41%5.44%3.90%-102.36%
R&D----1.72B2.51B1.66B1.84B1.58B1.57B3.87B
R&D as % of Total Revenue----43.89%109.41%38.46%20.77%14.53%13.59%30.10%
Interest Expense000090.20M144.67M458.92M1.27B1.43B1.81B1.92B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%2.30%6.32%10.66%14.34%13.21%15.69%14.97%

Balance Sheet

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets3.79B5.48B11.70B23.21B20.79B35.24B28.41B29.97B54.21B65.20B
Total Liabilities3.30B5.05B2.83B5.40B13.15B22.81B22.97B21.25B25.07B36.25B
Total Equity497.71M425.11M8.87B17.81B7.64B12.43B5.44B8.72B29.14B28.95B
Cash-2.95M2.35M2.35B2.24B1.50M2.23M1.14B12.61B16.27B
Total Debt-616.67M1.04B1.81B8.16B-----
Net Debt----5.15B8.96B11.99B11.72B2.59B6.65B

Cash Flow

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow13.09M225.20M331.81M-1.44B-5.12B-5.81B-6.96B-3.79B-4.25B-6.86B-5.62B
Investing Cash Flow66.92M-845.28M-570.18M-2.19B-13.56B-408.22M-10.59B1.40B6.60B-3.57B-
Financing Cash Flow-90.87M643.16M1.76B7.96B15.11B6.09B16.79B2.14B-2.42B21.89B-
Capital Expenditure27.18M67.78M347.46M767.21M2.62B4.08B2.20B4.18B1.37B1.97B7.88B
Free Cash Flow-----9.80B-9.19B-8.44B-10.16B-5.62B-8.83B-13.50B
FCF to OCF----191.42%158.18%121.16%267.89%132.10%128.68%240.18%

Earnings

Report DateJun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-----------------------------
EPS Actual-163.56-173.91-101.63-53.67-107.85-97.63-459.31-52.23-67.45-134.73-270.83-4.48-26.23-138.14-454.61-45.53-43.5511.07116.232.0842.19-30.2919.01-69.71-198.94-12.94-430.19-229.34-433.72
Surprise-----------------------------
Timing-----------------------------

Key Statistics & Ratios

Market Cap10.00B
Enterprise Value25.89B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.78
Price / Book0.66
Revenue (TTM)12.84B
Gross Profit (TTM)3.59B
EBITDA-7.08B
Profit Margin-102.36%
Operating Margin-273.10%
Return on Equity-45.26%
Return on Assets-9.87%
Shares Outstanding18.60M
Shares Float14.69M
Beta0.97
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • May 26, 20222:1
  • Jul 2, 20202:1